Forecast

The analysts' average price target is +5,05€ (+279,70%). The median is +5,15€ (+287,22%).

Buy	15
Hold	7
Sell	0

News Go to news feed

Geron reports RYTELO revenue growth and tightens 2026 outlook toward mid‑high guidance

Geron achieved 17% year-over-year net revenue growth for RYTELO and 24% net revenue growth in H1 2026 while cutting total operating expenses by 4%, driven by a refocused commercial push into high-volume community treatment centers. Management reiterated 2026 RYTELO revenue guidance at the mid-to-high end of $220–240 million, maintained total operating expense guidance of $230–240 million, and holds $327 million in cash to fund commercial investment. The company is evaluating an IMpactMF interim analysis event-threshold change with regulators, plans a gated European commercialization strategy, and expects final overall survival results in relapsed/refractory myelofibrosis in H2 2028. » More on finance.yahoo.com
Geron surpasses Q2 revenue forecast thanks to RYTELO, but remains unprofitable

Geron reported revenue of $57.48 million in the second quarter of 2026, 4.1% above analysts' estimates, driven by higher RYTELO sales. Adjusted loss per share was $0.02, missing expectations by $0.01, while operating expenses in the first half fell 4%. Management expects to finish the year at the mid-to-upper end of its revenue guidance ($220–240 million) and sees continued commercial momentum despite ongoing losses. » More on de.investing.com
Geron grants 690,000 inducement stock options to new employees

Effective June 17, 2026, Geron granted stock options to purchase 690,000 shares to eight newly hired employees as inducements for employment. The options carry an exercise price of $1.23 (closing price on grant date), a ten-year term and vest over four years, with 12.5% vesting at six months and the remainder vesting in equal installments over the following 42 months, subject to continued employment. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Geron Co. has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Geron Co. had revenue of 50,36 Mio€ and net profit of −14,62 Mio€

(EUR)	Jun 2026	YoY
Revenue	+50,36 Mio	21,06%
Gross profit	+42,27 Mio	4,13%
Net profit	−14,62 Mio	5,20%
EBITDA	−10,82 Mio	68,95%

Fundamentals

Metric	Value
Market capitalization	+842,27 Mio€
Number of shares	641,52 Mio
52-week high/low	+1,72€ - +0,89€
Dividends	No
Beta	0,59
P/E ratio	−15,35
PEG ratio	−0,70
P/B ratio	+4,69
P/S ratio	+4,80

Company profile

Geron Corporation, ein biopharmazeutisches Unternehmen in der Spätphase der klinischen Entwicklung, konzentriert sich auf die Entwicklung und Vermarktung von Therapeutika für myeloische hämatologische Malignome. Es entwickelt Imetelstat, einen Telomerase-Inhibitor, der sich in klinischen Studien der Phase 3 befindet und die unkontrollierte Proliferation bösartiger Stamm- und Vorläuferzellen in hämatologischen myeloischen Malignomen zur Behandlung von myelodysplastischen Syndromen mit niedrigem oder mittlerem Risiko sowie Myelofibrose mit mittlerem oder hohem Risiko hemmt. Das Unternehmen wurde 1990 gegründet und hat seinen Hauptsitz in Foster City, Kalifornien.